Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival.

Purpose To determine if preoperative vascular heterogeneity of glioblastoma is predictive of overall survival of patients undergoing standard-of-care treatment by using an unsupervised multiparametric perfusion-based habitat-discovery algorithm. Materials and Methods Preoperative magnetic resonance (MR) imaging including dynamic susceptibility-weighted contrast material-enhanced perfusion studies in 50 consecutive patients with glioblastoma were retrieved. Perfusion parameters of glioblastoma were analyzed and used to automatically draw four reproducible habitats that describe the tumor vascular heterogeneity: high-angiogenic and low-angiogenic regions of the enhancing tumor, potentially tumor-infiltrated peripheral edema, and vasogenic edema. Kaplan-Meier and Cox proportional hazard analyses were conducted to assess the prognostic potential of the hemodynamic tissue signature to predict patient survival. Results Cox regression analysis yielded a significant correlation between patients' survival and maximum relative cerebral blood volume (rCBVmax) and maximum relative cerebral blood flow (rCBFmax) in high-angiogenic and low-angiogenic habitats (P < .01, false discovery rate-corrected P < .05). Moreover, rCBFmax in the potentially tumor-infiltrated peripheral edema habitat was also significantly correlated (P < .05, false discovery rate-corrected P < .05). Kaplan-Meier analysis demonstrated significant differences between the observed survival of populations divided according to the median of the rCBVmax or rCBFmax at the high-angiogenic and low-angiogenic habitats (log-rank test P < .05, false discovery rate-corrected P < .05), with an average survival increase of 230 days. Conclusion Preoperative perfusion heterogeneity contains relevant information about overall survival in patients who undergo standard-of-care treatment. The hemodynamic tissue signature method automatically describes this heterogeneity, providing a set of vascular habitats with high prognostic capabilities. © RSNA, 2018.

[1]  Steven D Chang,et al.  Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment , 2016, Neuro-oncology.

[2]  Douglas C. Miller,et al.  Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.

[3]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[4]  J P B O'Connor,et al.  Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours. , 2011, The British journal of radiology.

[5]  Scott N. Hwang,et al.  Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. , 2014, Radiology.

[6]  Glyn Johnson,et al.  Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. , 2002, Radiology.

[7]  J. Raizer,et al.  Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study. , 2010, Radiology.

[8]  Luke Macyszyn,et al.  Pattern analysis of dynamic susceptibility contrast-enhanced MR imaging demonstrates peritumoral tissue heterogeneity. , 2014, Radiology.

[9]  Susan M. Chang,et al.  Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. , 2005, AJNR. American journal of neuroradiology.

[10]  Dafna Ben Bashat,et al.  Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study. , 2014, European journal of radiology.

[11]  M R Segal,et al.  Distinguishing Recurrent Intra-Axial Metastatic Tumor from Radiation Necrosis Following Gamma Knife Radiosurgery Using Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging , 2008, American Journal of Neuroradiology.

[12]  Leif Østergaard,et al.  Principles of cerebral perfusion imaging by bolus tracking , 2005, Journal of magnetic resonance imaging : JMRI.

[13]  Wanyong Shin,et al.  Quantitative cerebral MR perfusion imaging: Preliminary results in stroke , 2010, Journal of magnetic resonance imaging : JMRI.

[14]  David Gutman,et al.  Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. , 2013, Radiology.

[15]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.

[16]  A. Kyritsis,et al.  Mechanisms of angiogenesis in gliomas , 2006, Journal of Neuro-Oncology.

[17]  José V. Manjón,et al.  Automated Glioblastoma Segmentation Based on a Multiparametric Structured Unsupervised Classification , 2015, PloS one.

[18]  A. Bjørnerud,et al.  Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. , 2008, Radiology.

[19]  Helena Borges,et al.  Glioblastoma cells: a heterogeneous and fatal tumor interacting with the parenchyma. , 2011, Life sciences.

[20]  Sanjeev Chawla,et al.  Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. , 2012, Neuro-oncology.

[21]  Gang Wang,et al.  Diffusion and perfusion weighted magnetic resonance imaging for tumor volume definition in radiotherapy of brain tumors , 2016, Radiation Oncology.

[22]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[23]  Luis Martí-Bonmatí,et al.  Quantitative MR perfusion parameters related to survival time in high-grade gliomas , 2013, European Radiology.

[24]  T. Hirai,et al.  Prognostic Value of Perfusion MR Imaging of High-Grade Astrocytomas: Long-Term Follow-Up Study , 2008, American Journal of Neuroradiology.

[25]  Glyn Johnson,et al.  Comparison of region‐of‐interest analysis with three different histogram analysis methods in the determination of perfusion metrics in patients with brain gliomas , 2007, Journal of magnetic resonance imaging : JMRI.

[26]  Juan Miguel García-Gómez,et al.  An Online Platform for the Automatic Reporting of Multi-parametric Tissue Signatures: A Case Study in Glioblastoma , 2016, BrainLes@MICCAI.

[27]  D. Zagzag,et al.  Mechanisms of glioma-associated neovascularization. , 2012, The American journal of pathology.

[28]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[29]  B. Rosen,et al.  Tracer arrival timing‐insensitive technique for estimating flow in MR perfusion‐weighted imaging using singular value decomposition with a block‐circulant deconvolution matrix , 2003, Magnetic resonance in medicine.

[30]  Carlos Sáez,et al.  Stability metrics for multi-source biomedical data based on simplicial projections from probability distribution distances , 2017, Statistical methods in medical research.

[31]  S. Su,et al.  IDH mutations in glioma and acute myeloid leukemia. , 2010, Trends in molecular medicine.

[32]  J. Lemée,et al.  Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone. , 2015, Neuro-oncology.

[33]  Linda Knutsson,et al.  Absolute quantification of perfusion using dynamic susceptibility contrast MRI: pitfalls and possibilities , 2010, Magnetic Resonance Materials in Physics, Biology and Medicine.

[34]  Jianhui Zhong,et al.  Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. , 2010, Radiology.

[35]  Simona Marzi,et al.  Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation , 2012, Journal of experimental & clinical cancer research : CR.

[36]  E. Liouta,et al.  Prognostic value of preoperative dynamic contrast-enhanced MRI perfusion parameters for high-grade glioma patients , 2016, Neuroradiology.